Home Cart Sign in  
Chemical Structure| 578-86-9 Chemical Structure| 578-86-9

Structure of Liquiritigenin
CAS No.: 578-86-9

Chemical Structure| 578-86-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Liquiritigenin is an estrogenic compound which fuctions as a selective agonist of the estrogen receptor ERβ and an partial agonist of ERα. It also has choleretic effect. Liquiritigenin is a flavanone extracted from glycyrrhiza uralensis with antitumour action.

Synonyms: 4',7-Dihydroxyflavanone

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Liquiritigenin

CAS No. :578-86-9
Formula : C15H12O4
M.W : 256.25
SMILES Code : O=C1C[C@@H](C2=CC=C(O)C=C2)OC3=C1C=CC(O)=C3
Synonyms :
4',7-Dihydroxyflavanone
MDL No. :MFCD00287289
InChI Key :FURUXTVZLHCCNA-AWEZNQCLSA-N
Pubchem ID :114829

Safety of Liquiritigenin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
U87 100 μM 24 h Enhanced ER β protein expression and nuclear translocation PMC3721065
U138 200 μM 72 h Inhibited cell proliferation PMC3721065
T98G 200 μM 72 h Inhibited cell proliferation PMC3721065
LN229 100 μM 24 h Enhanced ER β protein expression and nuclear translocation PMC3721065
MC3T3-E1 cells 0.5, 1.0, 5.0, 10.0 μM 48 h To evaluate the effect of LG on ALP activity in MC3T3-E1 cells, results showed LG increased ALP activity in a dose-dependent manner. PMC10066282
MC3T3-E1 cells 0.5, 1.0, 5.0, 10.0 μM 48 h To evaluate the effect of LG on MC3T3-E1 cell viability, results showed no significant effect on cell viability at concentrations below 10 μM. PMC10066282
Rat hippocampal neurons 0.02, 0.2, 2 μM 24 h To evaluate the protective effect of Liquiritigenin against Aβ 25–35-induced neurotoxicity. Results showed that Liquiritigenin increased cell viability in a concentration-dependent manner, reduced LDH leakage, inhibited increases in intracellular Ca2+ concentration and ROS levels, and decreased the apoptotic rate of neurons. PMC4006661
Raw264.7 cells 3–30 μM 1 h To evaluate the inhibitory effects of Liquiritigenin on LPS-induced NO production and iNOS expression. Results showed that Liquiritigenin significantly inhibited NO production and iNOS protein and mRNA expression in a concentration-dependent manner. PMC2438972
Caco-2 cells 10 μM 60 min To investigate the effect of Liquiritigenin on P-gp function, results showed that Liquiritigenin inhibited P-gp-mediated Rh-123 transport. PMC7192969
primary mouse lung fibroblasts 3 μM, 10 μM, 30 μM, 100 μM 48 h To evaluate the inhibitory effect of Liquiritigenin on TGF-β1-induced myofibroblast differentiation, results showed that Liquiritigenin effectively reversed the TGF-β1-induced increase in collagen I and α-SMA levels. PMC10795230
3T3-L1 cells 25 μM and 50 μM 72 h LQG significantly reduced triglyceride levels and downregulated the expression of transcription factors such as C/EBPα and PPARγ in 3T3-L1 adipocytes. PMC8954126

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57 mice Ovariectomy (OVX) osteoporosis mouse model Intragastric administration 30 mg/kg Once daily for 90 days To evaluate the effect of LG on bone loss in OVX mice, results showed LG significantly improved trabecular microstructure and reduced bone loss. PMC10066282
Sprague-Dawley rats Carrageenan-induced paw oedema model Oral or intravenous 50 mg/kg or 15 mg/kg Oral: once daily for 3 days; Intravenous: once daily for 2 days To evaluate the inhibitory effects of Liquiritigenin on carrageenan-induced acute inflammation. Results showed that Liquiritigenin significantly reduced paw oedema formation, with efficacy comparable to the positive control dexamethasone. PMC2438972
Sprague-Dawley rats Freund's adjuvant-induced inflammation model Oral 10 mg/kg Single dose To investigate the effect of Liquiritigenin on the pharmacokinetics of AC, results showed that Liquiritigenin increased the Cmax and AUC of AC. PMC7192969
APP/PS1 transgenic mice Ovariectomized to simulate postmenopausal low estrogen state Intragastric infusion 50 μg/kg Once daily for 4 consecutive weeks To evaluate the effects of combined treatment with Liquiritigenin and valproic acid on cognitive function and neuropathology in ovariectomized APP/PS1 mice. Results showed that combined treatment significantly improved spatial memory and learning, reduced Aβ deposition and tau hyperphosphorylation, promoted neuronal maturation, and improved synaptic structure and function. PMC8343327
Nude mice Subcutaneous xenograft model Subcutaneous injection 20 mg/kg Once daily for 30 days Significantly reduced tumor growth, increased ER β expression and nuclear localization PMC3721065
C57BL/6 mice Bleomycin-induced pulmonary fibrosis model Oral 25 mg/kg, 50 mg/kg, 100 mg/kg Once daily for 14 days To evaluate the therapeutic effect of Liquiritigenin on bleomycin-induced pulmonary fibrosis, results showed that Liquiritigenin significantly reduced the thickening of alveolar walls and deposition of extracellular matrix, and decreased mortality. PMC10795230

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.90mL

0.78mL

0.39mL

19.51mL

3.90mL

1.95mL

39.02mL

7.80mL

3.90mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories